# Research Project Plan: Osimertinib + EGFR ADC Combination Adverse Events

## Project Overview

**Research Question:** What are the likely adverse events associated with combining osimertinib (EGFR TKI) with a mutant EGFR-targeting antibody-drug conjugate (ADC)?

**Approach:** Multi-agent research system with agent mail communication, followed by rigorous multi-level audit

## Architecture

### Agent Roles

1. **Orchestrator** - Coordinates overall research, maintains minimal context
2. **LiteratureAgent** - Searches and analyzes scientific literature
3. **SafetyAnalysisAgent** - Specialized in adverse event profiling
4. **PharmacologyAgent** - Drug mechanism and interaction expert
5. **StatisticsAgent** - Quantitative risk assessment
6. **ClinicalAgent** - Clinical implications and recommendations
7. **AuditAgent** (multiple) - Quality control and validation
8. **CriticalAuditor** (Opus 4.1-level) - Deep critical analysis

### Communication Flow

```
Orchestrator
    ├─> Task 1 (Literature: Osimertinib) ─> LiteratureAgent ─> AuditAgent
    ├─> Task 2 (Literature: EGFR ADCs) ─> LiteratureAgent ─> AuditAgent
    ├─> Task 3 (Safety: Osimertinib) ─> SafetyAnalysisAgent ─> AuditAgent
    ├─> Task 4 (Safety: EGFR ADCs) ─> SafetyAnalysisAgent ─> AuditAgent
    ├─> Task 5 (Pharmacology: Interactions) ─> PharmacologyAgent ─> AuditAgent
    ├─> Task 6 (Statistics: Risk) ─> StatisticsAgent ─> AuditAgent
    └─> Task 7 (Clinical: Implications) ─> ClinicalAgent ─> AuditAgent

All communication via Agent Mail System
All results compressed before returning to Orchestrator
```

### Audit Architecture

```
Phase 1: Real-time Audits
- Each task output audited immediately
- Pass/Fail/Retry decisions

Phase 2: Comprehensive Audit
- Cross-task consistency check
- Evidence quality assessment
- Anti-fabrication compliance audit

Phase 3: Critical Audit (Opus 4.1-level)
- Deep methodological review
- "Claude cheat" detection
- Statistical rigor validation
- Evidence chain verification
```

## Research Tasks Breakdown

### Task 1: Osimertinib Literature Review
**Agent:** LiteratureAgent
**Objective:** Comprehensive safety profile of osimertinib
**Deliverables:**
- Common adverse events (frequency data)
- Serious adverse events
- Mechanism of toxicity
- FDA label warnings
- Clinical trial safety data
**Evidence Requirements:** Peer-reviewed publications, clinical trial data, FDA labels

### Task 2: EGFR ADC Literature Review
**Agent:** LiteratureAgent
**Objective:** Safety profile of EGFR-targeting ADCs
**Deliverables:**
- ADC-specific toxicities (payload-related, target-related)
- EGFR-mediated adverse events
- Clinical trial safety data
- Comparison across different EGFR ADCs
**Evidence Requirements:** Clinical trials, review articles, regulatory documents

### Task 3: Osimertinib Safety Deep Dive
**Agent:** SafetyAnalysisAgent
**Objective:** Detailed adverse event characterization
**Deliverables:**
- Organ system toxicity profile
- Dose-limiting toxicities
- Grade 3/4 adverse events
- Time to onset patterns
- Risk factors and predictors

### Task 4: EGFR ADC Safety Deep Dive
**Agent:** SafetyAnalysisAgent
**Objective:** ADC-specific toxicity mechanisms
**Deliverables:**
- On-target, off-tumor effects
- Off-target effects
- Payload-related toxicities
- Immunogenicity concerns
- Comparative toxicity vs other ADCs

### Task 5: Pharmacological Interaction Analysis
**Agent:** PharmacologyAgent
**Objective:** Mechanistic interaction assessment
**Deliverables:**
- Overlapping toxicity mechanisms
- PK/PD interactions
- Synergistic vs additive toxicity
- Target pathway saturation effects
- Resistance mechanism interactions

### Task 6: Statistical Risk Assessment
**Agent:** StatisticsAgent
**Objective:** Quantitative risk modeling
**Deliverables:**
- Predicted combined AE rates
- Risk ratios and confidence intervals
- Bayesian risk estimates
- Safety margin calculations
**Requirements:** Must cite methodology, no fabricated statistics

### Task 7: Clinical Implications
**Agent:** ClinicalAgent
**Objective:** Clinical risk-benefit assessment
**Deliverables:**
- Patient selection criteria
- Monitoring recommendations
- Dose modification strategies
- Management of predicted AEs
- Risk mitigation approaches

## Audit Checklist

### Level 1: Task-Level Audit (Real-time)
- [ ] All claims have citations
- [ ] No fabricated data
- [ ] Appropriate uncertainty expressions
- [ ] Required fields present
- [ ] Methodology described
- [ ] Limitations acknowledged

### Level 2: Comprehensive Audit
- [ ] Cross-task consistency
- [ ] No contradictions
- [ ] Evidence quality assessment
- [ ] Statistical validity
- [ ] Clinical plausibility
- [ ] CLAUDE.md compliance

### Level 3: Critical Audit (Opus 4.1-level)
- [ ] Deep literature verification
- [ ] Statistical methodology rigor
- [ ] Evidence chain completeness
- [ ] Bias detection
- [ ] Alternative interpretation consideration
- [ ] "Claude cheat" detection:
  - Fabricated percentages
  - Made-up study names
  - Invented mechanisms
  - Unsupported causal claims
  - Overconfident predictions
  - Missing caveats

## Output Requirements

### Research Report Structure
1. Executive Summary
2. Osimertinib Safety Profile
3. EGFR ADC Safety Profile
4. Predicted Combination Toxicities
5. Mechanistic Rationale
6. Statistical Risk Assessment
7. Clinical Recommendations
8. Limitations and Uncertainties
9. References

### Audit Report Structure
1. Audit Methodology
2. Task-by-Task Findings
3. Critical Issues Identified
4. "Claude Cheats" Detected
5. Evidence Quality Assessment
6. Statistical Review
7. Recommendations for Improvement
8. Revision Task List

## Success Metrics

- All tasks completed with audit approval
- Evidence chain complete for all claims
- No fabricated data detected
- Statistical methods validated
- Clinical recommendations defensible
- Comprehensive audit identifies all weaknesses
- Actionable revision task list generated

---

**Status:** Planning complete, ready for execution
